PPARG and stroke disorder: Delayed treatment with the anti-inflammatory PPAR-γ agonist pioglitazone, but not the CB2R agonist AM1241, reduced IBA1 expression in the stroke cortex and improved neurological function while pretreatment with AM1241 reduced brain damages.